Cargando…

PA03.06. Swertiamarin A novel lead to antidepressants

PURPOSE: Conventional medicine says depression is a psychological disorder due to imbalance of neurotransmitters in the brain and that which thereby focuses on managing depression rather than curing it. Contrary, ayurveda treats depression in a gentle, natural and effective way. Identification of li...

Descripción completa

Detalles Bibliográficos
Autores principales: Dharaniyambigai, K, Doss, VA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147549/
http://dx.doi.org/10.4103/0257-7941.123898
_version_ 1782332469287059456
author Dharaniyambigai, K
Doss, VA
author_facet Dharaniyambigai, K
Doss, VA
author_sort Dharaniyambigai, K
collection PubMed
description PURPOSE: Conventional medicine says depression is a psychological disorder due to imbalance of neurotransmitters in the brain and that which thereby focuses on managing depression rather than curing it. Contrary, ayurveda treats depression in a gentle, natural and effective way. Identification of ligands and phy tochemi c a l s tha t a re respons ible for antidepressant activity in plants are necessary in order to develop efficient drugs that are rapid and effective naturally without side effects even in acute administration. METHOD: Swertiamarin an unique phytochemical of the Gentianaceae family is a secoiridoid glucoside, is purified and quantified from sources namely Enicostemma littorale, Swertia chirata, S.japonica and S.angustifolia using HPLC with ethyl acetate: methanol: water (7.7:2.0:0.5) solvent systems. This purified phytochemical, hypothesized to possess antidepressant activity is then subjected to structure elucidation using mass spectrophotometer and Xray diffraction studies and proceeded with homology modeling for docking the swertiamarin with imipramine, citalopram, fluoxetine and venlafaxine receptors (antidepressant sites). The purified swertiamarin is further subjected to clinical and biochemical parameter analysis thereby analysing its potential to treat the depression induced in animals (group study) comparison with the standard allopathic antidepressants. RESULT: The source rich in swertiamarin can be determined using HPLC and are considered for further clinical and therapeutic parameters. The comparative structure elucidation of swertiamarin with MS and Xray diffraction analysis from various sources under study can predict the diversity of the compound which can serve as basis for functional analysis. The modeling and docking studies reveal the interactions of swertiamarin with its receptors (site of action) whose understanding can aid in revealing its mechanism as an antidepressant. Besides these, the clinical trials in shows the efficiency of swertiamarin as an antidepressant when compared to other drugs. CONCLUSION: This study can provide basis for improvement of ayurvedic antidepressants through phytochemical and clinical research which can aid gentler and quick treatment that can result from low and acute doses.
format Online
Article
Text
id pubmed-4147549
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41475492014-10-02 PA03.06. Swertiamarin A novel lead to antidepressants Dharaniyambigai, K Doss, VA Anc Sci Life Poster Presentation PURPOSE: Conventional medicine says depression is a psychological disorder due to imbalance of neurotransmitters in the brain and that which thereby focuses on managing depression rather than curing it. Contrary, ayurveda treats depression in a gentle, natural and effective way. Identification of ligands and phy tochemi c a l s tha t a re respons ible for antidepressant activity in plants are necessary in order to develop efficient drugs that are rapid and effective naturally without side effects even in acute administration. METHOD: Swertiamarin an unique phytochemical of the Gentianaceae family is a secoiridoid glucoside, is purified and quantified from sources namely Enicostemma littorale, Swertia chirata, S.japonica and S.angustifolia using HPLC with ethyl acetate: methanol: water (7.7:2.0:0.5) solvent systems. This purified phytochemical, hypothesized to possess antidepressant activity is then subjected to structure elucidation using mass spectrophotometer and Xray diffraction studies and proceeded with homology modeling for docking the swertiamarin with imipramine, citalopram, fluoxetine and venlafaxine receptors (antidepressant sites). The purified swertiamarin is further subjected to clinical and biochemical parameter analysis thereby analysing its potential to treat the depression induced in animals (group study) comparison with the standard allopathic antidepressants. RESULT: The source rich in swertiamarin can be determined using HPLC and are considered for further clinical and therapeutic parameters. The comparative structure elucidation of swertiamarin with MS and Xray diffraction analysis from various sources under study can predict the diversity of the compound which can serve as basis for functional analysis. The modeling and docking studies reveal the interactions of swertiamarin with its receptors (site of action) whose understanding can aid in revealing its mechanism as an antidepressant. Besides these, the clinical trials in shows the efficiency of swertiamarin as an antidepressant when compared to other drugs. CONCLUSION: This study can provide basis for improvement of ayurvedic antidepressants through phytochemical and clinical research which can aid gentler and quick treatment that can result from low and acute doses. Medknow Publications & Media Pvt Ltd 2013-01 /pmc/articles/PMC4147549/ http://dx.doi.org/10.4103/0257-7941.123898 Text en Copyright: © Ancient Science of Life http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Presentation
Dharaniyambigai, K
Doss, VA
PA03.06. Swertiamarin A novel lead to antidepressants
title PA03.06. Swertiamarin A novel lead to antidepressants
title_full PA03.06. Swertiamarin A novel lead to antidepressants
title_fullStr PA03.06. Swertiamarin A novel lead to antidepressants
title_full_unstemmed PA03.06. Swertiamarin A novel lead to antidepressants
title_short PA03.06. Swertiamarin A novel lead to antidepressants
title_sort pa03.06. swertiamarin a novel lead to antidepressants
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147549/
http://dx.doi.org/10.4103/0257-7941.123898
work_keys_str_mv AT dharaniyambigaik pa0306swertiamarinanovelleadtoantidepressants
AT dossva pa0306swertiamarinanovelleadtoantidepressants
AT pa0306swertiamarinanovelleadtoantidepressants